Research and Markets: Procter & Gamble Is Collaborating on the Development and Commercialisation of Alexion Pharmaceutical's Lead C5 Complement Inhibitor Drug Candidate, Pexelizumab.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c47214) has announced the addition of Espicom Business Intelligence's Procter & Gamble Prospects to 2010 to their offering. Founded in 1837, Procter & Gamble (P&G) is a diversified company diversified company A company engaged in varied business operations not directly related to one another. A diversified company is less likely to suffer either a collapse or a spectacular gain in earnings compared with a firm concentrating its operations in a which manufactures and markets a broad range of laundry, cleaning, paper, beauty care, healthcare, food and beverage F&B is a common abbreviation in the United States and Commonwealth countries, including Hong Kong. F&B is typically the widely accepted abbreviation for "Food and Beverage," which is the sector/industry that specializes in the conceptualization, the making of, and delivery of foods. products. P&G markets nearly 300 brands covering about 50 product categories, in more than 160 countries around the world. It has a workforce of over 110,000 people and invests approximately US$2.0 billion per year in research and development. The Health Care division develops pharmaceuticals, oral and personal health care products and is a major component of P&G's Beauty and Health Global Business Unit. Current Growth Drivers Actonel (risedronate), a third-generation, once-daily bisphosphonate, is P&G's only major pharmaceutical product. P&G and sanofi-aventis formed The Alliance for Better Bone Health in May 1997, to develop and market Actonel, with the companies co-promoting it in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. and in select key markets in Europe. Key Late-Stage Products P&G is collaborating on the development and commercialisation of Alexion Pharmaceutical's lead C5 complement inhibitor inhibitor /in·hib·i·tor/ (in-hib´i-tor) 1. any substance that interferes with a chemical reaction, growth, or other biologic activity. 2. drug candidate, pexelizumab. This drug is a novel, bacterially-produced, humanised, single-chain antibody, specifically designed to rapidly penetrate tissue and limit inflammation. Key Early-Stage Products P&G has forged a strategic alliance under which it will develop and commercialise ARYx Therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. novel drug, ATI-7505, for the treatment of gastrointestinal disorders Noun 1. gastrointestinal disorder - illness caused by poisonous or contaminated food food poisoning illness, sickness, unwellness, malady - impairment of normal physiological function affecting part or all of an organism such as gastro-oesophageal reflux reflux /re·flux/ (re´fluks) a backward or return flow. duodenogastric reflux reflux of the contents of the duodenum into the stomach; it may occur normally, especially during fasting. disease and gastroparesis. Products Mentioned Include: Actonel (risedronate) Principal Operating Results Latest Results Content Outline: Executive Summary Introduction Current Growth Drivers Key Late-Stage Products Key Early-Stage Products Financial performance 2006 Sales and market position Income Expenditure Capital Expenditure Capital Expenditures By Business Area R&D Expenditure Divisional Performance Sales By Business Area Net Income By Business Area Total Assets By Business Area Sales By Geographic Area Company strategy Mergers, Acquisitions and Divestitures Key Agreements Production Product / R&D Overview Key Products Recent Product Launches Recent Product Approvals R&D Pipeline Overview Conclusions PRODUCT PORTFOLIO/ RESEARCH AND DEVELOPMENT Major Products and Therapeutic Areas R&D Pipeline Musculoskeletal musculoskeletal /mus·cu·lo·skel·e·tal/ (-skel´e-t'l) pertaining to or comprising the skeleton and muscles. mus·cu·lo·skel·e·tal adj. Relating to or involving the muscles and the skeleton. Products Major Launched Products Actonel Sales Key Markets/Indications Safety Issues Patents/Generic Competition Lawsuits Competitor Products Generic Competition Didronel/Didronate Key Markets/Indications Competitor Products Others Musculoskeletal R&D PTH PTH abbr. parathyroid hormone Parathyroid hormone (PTH) A chemical substance produced by the parathyroid glands. This hormone is a major element in regulating calcium in the body. (1-34) Clinical Trial Results Musculoskeletal Summary Growth Potential Limiting Factors A factor or condition that, either temporarily or permanently, impedes mission accomplishment. Illustrative examples are transportation network deficiencies, lack of in-place facilities, malpositioned forces or materiel, extreme climatic conditions, distance, transit or overflight rights, Gastrointestinal gastrointestinal /gas·tro·in·tes·ti·nal/ (-in-tes´ti-n'l) pertaining to or communicating with the stomach and intestine. gas·tro·in·tes·ti·nal adj. Abbr. Products Major Launched Products Asacol Sales Key Markets/Indications/Formulations Patents Competitor Products Gastrointestinal R&D ATI-7505 RDP (Remote Desktop Protocol) The presentation services protocol that governs input/output between a Windows terminal client and Windows Terminal Server. It is based on the T.share protocol. See Windows Terminal Server. (protocol) RDP - 1. 58 Gastrointestinal Summary Anti-infectives Products Major Launched Products Macrodantin/Furadantin/Macrobid Key Markets/Indications/Formulations Patents Generic Competition Others Anti-Infective Summary Cardiovascular Products Cardiovascular R&D Pexelizumab Clinical Trial Results Coronary Artery Bypass Graft Surgery Coronary Artery Bypass Graft Surgery Definition Coronary artery bypass graft surgery is a surgical procedure in which one or more blocked coronary arteries are bypassed by a blood vessel graft to restore normal blood flow to the heart. Cardiovascular Summary Growth Potential Limiting Factors Others Products Oral Health Care Others APPENDIX 1 FINANCIAL PERFORMANCE Full Year Results 2006 APPENDIX 2 KEY AGREEMENTS Alexion Pharmaceuticals Inc 12th December 2001 ARYx 11th July 2006 AstraZeneca 18th November 2004 Chemokine chemokine /che·mo·kine/ (ke´mo-kin) any of a group of low molecular weight cytokines identified on the basis of their ability to induce chemotaxis or chemokinesis in leukocytes (or in particular populations of leukocytes) in inflammation. Therapeutics Corporation 23rd September 2004 Cincinnati Children's Hospital A children's hospital is a hospital which offers its services exclusively to children. The number of children's hospitals proliferated in the 20th century, as pediatric medical and surgical specialties separated from internal medicine and adult surgical specialties. Medical Centre 22nd February 2005 Curis Inc 19th September 2005 21st March 2006 4th October 2006 Genzyme Corporation 1st April 2004 Nastech Pharmacecutical 1st February 2006 6th June 2006 8th June 2006 Novartis 6th July 2005 sanofi-aventis 5th May 1997 8th October 2004 TaiGen Biotechnology Co Ltd 5th January 2005 18th June 2005 Licensing Agreements APPENDIX 3 INFRASTRUCTURE Manufacturing Facilities Research and Development Facilities APPENDIX 4 MAJOR PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES APPENDIX 5 PRODUCT INDEX Index of Tables Principal Operating Results Capital Expenditures By Business Area Sales By Business Area Net Income By Business Area Total Assets By Business Area Sales By Geographic Area Recent Product Launches Recent Product Approvals Major Products and Therapeutic Areas R&D Pipeline Major Launched Products Major Launched Products Major Launched Products Index of Charts Capital Expenditure By Business Area, 2006 Sales By Business Area, 2006 Net Income By Business Area Sales by Geographic Area, 2006 Sales, Costs and Operating Income Operating Income The profit realized from a business' own operations. Notes: This would not include income from things such as investments in other firms. Also referred to as operating profit or recurring profit. Profitability and Research Ratios R&D Expenditure and Capital Expenditure Current Assets Current Assets Appearing on a company's balance sheet, it represents cash, accounts receivable, inventory, marketable securities, prepaid expenses, and other assets that can be converted to cash within one year. , Liabilities and Ratio Assets, Cash and Liquidity Employees and Productivity Pharmaceutical Company Intelligence Reports provide a full review of the companys activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 40 Company Intelligence Reports are currently available. Companies Mentioned: - Alexion Pharmaceuticals Inc - ARYx - AstraZeneca - Chemokine Therapeutics Corporation - Cincinnati Children's Hospital Medical Centre - Curis Inc - Genzyme Corporation - Nastech Pharmacecutical - Novartis - sanofi-aventis - TaiGen Biotechnology Co Ltd For more information visit http://www.researchandmarkets.com/reports/c47214 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion